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The NADPH oxidase of human eosinophils, measured in the cell-free system, shows the same characteristics as the enzyme from human neutrophils. 
All proteins required for activity of the enzyme are expressed in eosinophils at a higher level than in neutrophils. Eosinophils isolated from patients 
with chronic granulomatous disease show the same molecular defects as the neutrophils fom these patients. 
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INTRODUCTION 
Eosinophilic granulocytes are important cells in the 
host defense against pathogenic parasites and micro- 
organisms. When challenged with appropriate stimuli, 
eosinophils - like neutrophilic granulocytes - pro- 
duce toxic oxygen metabolites by means of a 
membrane-bound NADPH oxidase [ 1,2]. A b-type 
cytochrome (cytochrome b558) is a component of this en- 
zyme. Eosinophils contain a 2-3-fold higher amount of 
cytochrome b558 than neutrophils as determined by ab- 
sorption spectroscopy [3]. In neutrophils from patients 
with X-linked cytochrome &g-negative chronic 
granulomatous disease (Xb- CGD), this cytochrome is 
absent [4]. 
Recently, it was found that the neutrophil NADPH 
oxidase can be activated in a cell-free system by addi- 
tion of sodium dodecyl sulfate or arachidonic acid 
[5-71. This cell-free system requires both a plasma 
membrane and a cytosolic fraction [6]. Two to four 
cytosolic components from neutrophils have been 
described that act in concert [I&10]. Two of these com- 
ponents have been characterized as a phosphoprotein of 
M, 47 000 (~~47) [8,9,1 l] and a protein of Mr 67 000 
(~67) [9,11], respectively. Two forms of autosomal 
cytochrome &g-positive chronic granulomatous 
disease (AB+ CGD) exist that lack either protein in the 
neutrophils [ 121. 
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In this report we compared the NADPH oxidase of 
human eosinophils with that of human neutrophils. 
Eosinophil NADPH oxidase too can be activated in a 
cell-free system with SDS. In addition, cytosol from 
eosinophils can elicit activity in neutrophil plasma 
membranes and vice versa. Thus eosinophils express at 
least twice as much of the proteins required for 
NADPH oxidase activity as do neutrophils. 
MATERIALS AND METHODS 
2.1. Materials 
Phenylmethylsulfonyl fluoride (PMSF), acetyl-l-leucyl-l-leucyl- 
L-arginine (leupeptin), N-2-hydroxyethylpiperazine-N’-2-ethanesul 
fonic acid (hepes), platelet-activating factor (PAF; L-a-phosphatidyl- 
choline, P-acetyl, y-0-hexadecyl) and N-succinimidyl3-(2-pyridyldit- 
hio)propionate (SPDP) were from Sigma Co., St Louis, MO, USA. 
Keyhole Limpet Hemocyanin (KLH) was obtained from Calbiochem, 
San Diego, CA, USA. Guanosine 5’-0-(3-thiotriphosphate) (GTP-Y- 
S) and NADPH were purchased from Boehringer, Mannheim, FRG. 
Phorbol myristic acetate (PMA) was from Consolidated Midland 
Corp., Katonah, NY, USA. Serum-treated zymosan was prepared as 
described before [12]. Reagents and molecular-weight markers for 
SDS-polyacrylamide gelelctrophoresis (SDS-PAAGE) were from Bio- 
Rad Laboratories, Richmond, CA, USA. 
2.2. Assays for marker enzymes and proteins 
For measurement of eosinophil peroxidase activity, samples were 
diluted 1: 1 with 1% (w/v) cetyltrimethylammonium bromide 
(CETAB) and shaken vigorously. Samples were centrifuged uring 10 
min at 10 000 x g and 25 and 50 ~1 of the clear supernatant were tested 
for EPO activity. The assay mixture contained 50 mM potassium 
phosphate, 50 rM KBr, 100 pM Hz02 and 40 gM 
monochlorodimedon, pH 4.0. The reaction was started by the addi- 
tion of enzyme, and the decrease in absorbance at 280 nm was re- 
corded. 
Activities of alkaline phosphatase and lactate dehydrogenase were 
measured as described by Borregaard et al. [14]. Protein concentra- 
tions were determined with the BCA protein assay (Pierce Chemical 
Co., Rockford, IL, USA). 
2.3. Isolation and fractionation of granulocytes 
Eosinophils were isolated at 3 occasions from the buffy coats of 500 
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ml of healthy-donor blood, according to Koenderman et al. [15]. The 
purity of the isolated eosinophils was 99% in all cases. Neutrophils 
were isolated as previously described [16]. At one occasion 
eosinophils were isolated from CGD patients. One patient was 
classified as X-linked cytochrome bsss-negative (Xb - ) and the other 
as autosomal cytochrome-&-positive (AB+) [16]. From the Xb- 
CGD patient 10’ eosinophils were purified from 50 ml of blood, and 
from the Ab + CGD patient 3 x lo6 from 25 ml of blood. 
For fractionation of normal eosinophils, the cells were suspended 
in 0.34 M sucrose, 10 mM Hepes, 1 mM EGTA, 1 mM PMSF, 100 CM 
leupeptin in PBS, pH 7.0, at a concentration of 2 x lo7 cells/ml. The 
cells were disrupted by sonication for three 15-s intervals at 21 kHz 
frequency and 8 cm peak-to-peak amplitude. The sonicate was cen- 
trifuged during 10 min at 800 x g to remove nuclei and unbroken cells. 
Aliquots (1.3 ml) of the supernatant were layered on top of discon- 
tinuous gradients of 1.5 ml 40% (w/v) sucrose and 1 ml 15% sucrose 
(w/v). The gradient was centrifuged uring 60 min at 100 000 x g. The 
application zone (referred to as cytosol), the interface between the 
15%/40% sucrose layer (referred to as plasma membranes) and the 
fraction on the bottom of the tube (referred to as granules) were 
harvested and stored at -70°C until further use. 
Neutrophils were fractionated in a similar way, except that a 
15%/50% (w/v) sucrose gradient was used. The interface of the 
sucrose layers contained essentially all the plasma membranes and 
specific granules. 
2.4. Immunoblotting with monoclonal antibodies 449 and 48 
SDS-PAGE followed by immunoblotting with monoclonal (Moab) 
449 and Moab 48, directed against the o-chain and P-chain of 
cytochrome b558, respectively, was performed as described by 
Verhoeven et al. [18]. 
2.5. Immunoblot with polyclonal rabbit antiserum B-I 
Twenty-five pg of cytosol protein were separated by SDS PAGE on 
90/a slab gels, and blotted onto nitrocellulose sheets. Development of 
the sheets with polyclonal antiserum B-l was performed as described 
in [ll]. 
4,2.6. Production of polyclonal antiserum PS-47-23 
A peptide corresponding to the amino acids 214-223 of the pp47 
NADPH oxidase component [19] was synthesized with an extra N- 
terminal cysteine. Ten mg of peptide was linked to 30 mg of KLH with 
SPDP as a linker. The conjugate (250 cg) was injected intramuscular 
in a New Zealand White rabbit, followed by two booster injections. 
On an immunoblot with neutrophil cytosol the antiserum reacted 
specifically with a protein of 47 kDa. No reaction was observed with 
cytosol from neutrophils derived from Ab + CGD patients. 
2.7. Measurement of NADPH oxidase activity in the cell-free system 
NADPH oxidase activity was measured as the rate of oxygen coh- 
sumption with a Clark oxygen electrode at 27’C. The assay mixture 
(0.25 ml) was composed of oxidase buffer (10 mM Hepes, 10 mM 
potassium phosphate, 0.17 M sucrose, 25 mM NaCl, 0.5 mM EGTA, 
1 mM MgClz, 2 mM sodium azide, 10 pM GTP-7s; pH 7.0, 5 $8 of 
plasma membrane protein and 20 pg of cytosol protein. The reaction 
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Fig. 1. Western Blot of neutrophil and eosinophil cell fractions with 
MoAb 48 and MoAb 449. Fractions corresponding to 2x lo6 cell 
equivalents were run on a 5-15% SDS polyacrylamide gel, and 
Western blotting was performed as described in section 2. (lane 1) 
Neutrophil cytosol; (lane 2) neutrophil plasma membranes plus 
neutrophil specific granules (this contains all the neutrophil 
cytochrome bjss); (lane 3) eosinophil cytosol; (lane 4 ) eosinophil 
plasma membranes; and (lane 5) eosinophil granules. 
was initiated by the addition of 10 pl of SDS to a final concentration 
of 100 pM, as described by Bromberg and Pick [6]. The reaction vessel 
was closed, 3 min later NADPH was added to a final concentration 
of 250 FM, and the NADPH-dependent oxygen consumption was 
determined. 
2.8. Measurement of oxygen consumption by intact eosinophils 
Oxygen consumption was measured at 37°C with a Clark oxygen 
electrode. The eosinophils were suspended at a concentration of 
2 X lo6 cells per ml in 133 mM NaCl, 6 mM KCl, 1 mM MgSO.,, 20 
mM Hepes, 1.2 mM potassium phosphate, 5.5 mM glucose, and 0.5% 
(w/v) human albumin, pH 7.4. After 15 min of preincubation the 
stimulus was added and the oxygen consumption was recorded for 5 
min. The results are given as the maximum rate of oxygen consump- 
tion during this interval. 
RESULTS AND DISCUSSION 
3.1. Fractionation of eosinophils 
Table I shows the result of a fractionation of human 
eosinophils. Little cross-contamination was observed 
between the three major fractions. Especially, the 
Table I 
Fractionation of human eosinophils 
Fraction Protein Eosinophil peroxidase Lactate dehydrogenase 
(W of total) 
cytosol 51.8 f 3.2 0 98.4 f 1.1 
plasma membranes 8.0 & 2.2 0.5 + 0.2 0.8 * 0.2 
granules 40.2 +3.0 99.5 f 0.7 0.8 & 0.1 
At three occasions eosinophils were isolated from peripheral blood and fractionated as 
described in section 2. The amount of eosinophils was 45 x 106, 38 x lo6 and 52 x 106. The 
results are the means f SE. 
270 
Volume 268, number 1 FEBS LETTERS July 1990 
-67 kD 
-47 kD 
Fig. 2. Immunoblot with antiserum B-l. Samples containing 1 .f x lo6 
cell equivalents were run on a 5-15% SDS polyacrylamide gel, and 
Western blotting with antiserum B-l was performed as described in 
section 2. (lane 1) neutrophils; (lane 2) eosinophils. 
plasma membranes are essentially free of granule and 
cytosol markers. When we attempted to measure 
alkaline phosphatase as a plasma membrane marker we 
found neither activity in any of the fractions, nor in in- 
tact eosinophils. Because our eosinophils are essentially 
devoid of neutrophils, the activity of alkaline 
phosphatase reported in previous studies with 
eosinophils is most likely due to contaminating 
neutrophils [20]. The absence of alkaline phosphatase is 
not due to our methods of isolation, because alkaline 
phosphatase was also undetectable in eosinophils 
isolated by a different method [l]. 
We further characterized the plasma membrane frac- 
tion by estimation of the amount of cytochrome b558. It 
has been reported that eosinophils contain twice as 
much cytochrome b558 as do neutrophils [3]. Fig. 1 
shows a Western blot with the monoclonal antibodies 
Moab 449 and Moab 48, directed against the (x and p 
subunit of cytochrome bS58, respectively [IS]. The ma- 
jority of cytochrome b558 was found in the eosinophil 
plasma membrane fraction and little in the granule frac- 
tion. This was confirmed by absorption spectroscopy 
(not shown). Because cytochrome bss8 in eosinophils is 
mainly located in small cytoplasmic granules [21], it is 
likely that the interface between the 15% and 40% 
sucrose contains these granules as well. In addition, 
Fig. 1 shows that eosinophils contain both subunits of 
cytochrome bsss in higher quantities than neutrophils. 
For activation of the NADPH oxidase in neutrophils 
both membrane-bound and cytosolic proteins are re- 
quired [6]. Two cytosolic proteins have been 
characterized, a 47-kDa phosphoprotein [8,9,12] and a 
protein of 67 kDa [9,12], These proteins can be visualiz- 
ed by immunoblotting with a polyclonal rabbit an- 
tiserum B-l [l 11. Fig. 2 shows an immunoblot of 
Table II 
Activity of the NADPH oxidase in the cell-free system 
Source of cytosol Source of membranes 02 consumption 
(nmoI/min/mg membrane protein) 
neutropbils 
eosinophils 
neutrophils 
eosinophils 
eosinophils 
neutrophils 
eosinophils 
eosinophils 
neutrophils 
granules from eosinophils 
412 rt 80 
941 + 125 
649 f 3.5 
6% + 59 
118 f 18 
NADPH oxidase was measured in the cell-free system as described in section 2 with 5 ec& of 
plasma membrane protein and 20 pg of cytosol protein. Under these conditions the assay is 
rate-limited by both plasma membranes and cytosol. Values are the mean f SE of 3 ex- 
periments. 
Table III 
Respiratory burst activity of eosinophils from CGD patients 
Source of eosinophils Stimulus 02 consumption 
(nmol/min/ lo6 cells) 
Xb - -patient low6 M PAF + 1 mg/mt STZ 0.15 
Xb - -patient 200 nglmf PMA 0.06 
Ab + -patient 10m6 M PAF + 1 mg/ml STZ 0.30 
Ab ’ -patient 200 ng/ml PMA 0.08 
Control low6 M PAF + 1 mg/ml STZ 14.2 f 1.0 (n=5) 
Control 200 ng/ml PMA 16.1 +: 2.5 (n=S) 
Oxygen consumption was measured at 37°C with a Clark oxygen e&rode as outlined in sec- 
tion 2. Cells were preincubated uring 15 min before the stimulus was added, and the oxygen 
consumption was recorded for 5 min. PAF was added 2 min before the addition of STZ. The 
results show the maximum rate of oxygen consumption. For the control studies, the mean f 
SE are given. 
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Pig. 3. lmmunoblot of eosinophils from CGD patients with MoAb 
449 and MoAb 48 and polyclonal antiserum PS-47-23. (A) Detection 
of the (Y and /3 subunit of cytochrome bm. (B) Detection of the 47 
kDa protein with antiserum PS-47-23. (Lane 1) lo6 control eosino- 
phils; (lane 2) ld eosinophils from a patient with Xb - CGD; (lane 3) 
5 x 10’ eosinophils from a patient with Ab + CGD. 
cytosol from eosinophils and neutrophils with an- 
tiserum B-l. It is clear that both proteins are present in 
the cytosol of eosinophils. 
3.2. NADPH oxidase activity of eosinophils in the 
cell-free system 
Table II shows the activity of the NADPH oxidase in 
the cell-free system. Under conditions in which activity 
of the enzyme is rate-limited by both the membrane- 
bound and the cytosolic components, eosinophils ex- 
pressed approximately 2.5 times higher activity than 
neutrophils. When the plasma membrane fraction from 
eosinophils was replaced by the granule fraction, about 
10% of the activity was found. This agrees well with the 
amount of cytochrome bsss found in the granule frac- 
tion (Fig. 1). In addition, Table II shows that plasma 
membranes from eosinophils can be reconstituted with 
cytosol from neutrophils and vice versa, giving in- 
termediate values of oxygen consumption. These results 
strongly suggest hat eosinophils and neutrophils ex- 
press the same proteins required for the NADPH ox- 
idase. 
3.3. Eosinophils from patients with chronic granulo- 
matous disease 
To investigate whether eosinophils from CGD pa- 
tients have the same molecular defect as the neutrophils 
from these patients, we isolated eosinophilic granulo- 
cytes from two patients with chronic granulomatous 
disease (CGD). One patient was characterized as X- 
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linked cytochrome &s-negative (Xb-) and the other as 
autosomal cytochrome bsss-positive (Ab+). Neutro- 
phils from both patients failed to generate a respiratory 
burst when challenged by appropriate stimuli (not 
shown). Table III shows that eosinophils isolated from 
these patients showed no oxygen consumption with 
either PAF plus opsonized particles or PMA as a 
stimulus. This indicates that the genetic defect of these 
patients is manifested in their eosinophilic granulocytes 
as well. To characterize this further, an immunoblot 
was performed with eosinophils from both types of 
CGD patients. Fig. 3 shows that in the eosinophils from 
an Xb - patient both subunits of cytochrome bsss were 
absent, whereas in eosinophils from an Ab + patient the 
47 kDa protein was undetectable. 
3.4. Conclusions 
In this paper we have demonstrated that the NADPH 
oxidase of eosinophils can be activated in the cell-free 
system with SDS. In addition, we have shown that 
eosinophils express the same proteins as neutrophils, 
and the expression of these proteins in eosinophils is at 
least twice as high as in neutrophils. Genetic defects of 
these proteins are manifested both in neutrophils and in 
eosinophils. 
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